Michael R. Grunwald, MD, FACP

Articles

Dr Grunwald on the Patient Population and Limitations of the REVEAL Study in PV

September 4th 2024

Michael R. Grunwald, MD, FACP, discusses the characteristics of patients with polycythemia vera enrolled in the REVEAL study and limitations of the study.

The Future of AYA ALL

August 28th 2024

The panel concludes its discussion with a look at the future of AYA ALL treatment and the role of clinical trials and innovative therapies in improving outcomes for patients.

The Potential of Modified Treatment Regimens in AYA ALL

August 28th 2024

Experts on AYA ALL discuss the potential applicability of modified treatment regimens and the importance of multidisciplinary collaboration to meet the unique needs of patients.

CALBG 10403 in AYA ALL

August 21st 2024

A panel of experts discusses the use of CALBG 10403 in patients with AYA ALL, highlighting adverse events reported with the regimen and mitigation practices.

Clinical Scenario of a 32-Year-Old Female with AYA ALL and the Role of Cytogenetics in AYA ALL

August 21st 2024

Michael Grunwald, MD, presents the case of a 32-year-old woman with AYA ALL, and Kelly Weaver, NP, DNP, discusses the role of cytogenetics in diagnosing patients with AYA ALL.

ALL AYA: Coordination of Care

August 14th 2024

Experts on acute lymphoblastic leukemia discuss administration practices for asparaginase erwinia chrysanthemi and the importance of timely referrals and coordination of care.

Asparaginase Erwinia Chrysanthemi: Side Effects and Hypersensitivity Reactions

August 14th 2024

Kelly Weaver, NP, DNP, and Grace Elsey, PharmD, outline adverse effects associated with asparaginase erwinia chrysanthemi in patients with ALL and actions that can be taken to mitigate them.

Dr Grunwald on a Real-World Study of Risk Factors For Disease Progression in PV

August 9th 2024

Michael R. Grunwald, MD, discusses findings from a real-world study of risk factors related to disease progression in polycythemia vera.

AYA ALL: Role of Asparaginase Erwinia Chrysanthemi

August 7th 2024

Grace Elsey, PharmD, discusses the trial that led to the approval of asparaginase erwinia chrysanthemi and how it impacts AYA ALL treatment paradigms.

AYA ALL: Pediatric and Adult Inspired Regimens

August 7th 2024

Focusing on the current treatment landscape for patients with AYA ALL, the panel discusses clinical practices and treatment decisions based on age.

AYA ALL: Overview and Risk Stratification

July 31st 2024

Experts on acute lymphoblastic leukemia share their clinical experiences, describe high-risk features, and provide insights on risk stratification practices.

Clinical Scenario: A 23-Year-Old Male with AYA ALL

July 31st 2024

A panel of experts from Atrium Health Levine Cancer Institute present a patient case and provide an overview of adolescent and young adult (AYA) acute lymphoblastic leukemia (ALL).

Dr Grunwald on the Rates of Disease Progression in Low-Risk Myelofibrosis

June 15th 2024

Michael R. Grunwald, MD, FACP, discusses disease progression in patients with low-risk myelofibrosis enrolled in the prospective MOST study.

Dr. Grunwald on the Clinical Implications of Tisagenlecleucel in B-ALL Treatment

July 12th 2021

Michael R. Grunwald, MD, FACP, discusses the clinical implications of tisagenlecleucel in the treatment of patients with B-cell acute lymphoblastic leukemia.

Dr. Grunwald on the Established and Potential Utility of Tisagenlecleucel in ALL

May 5th 2021

Michael R. Grunwald, MD, FACP, discusses the established and potential utility of tisagenlecleucel in patients with acute lymphoblastic leukemia.

Dr. Grunwald on Preventing Relapse in Lymphoid and Myeloid Malignancies

May 4th 2021

Michael R. Grunwald, MD, FACP, discusses preventing relapse in patients with lymphoid and myeloid malignancies following allogeneic transplantation.

Dr. Grunwald on the Efficacy of 19-28z CAR T-Cell Therapy in B-ALL

April 27th 2021

Michael R. Grunwald, MD, FACP, discusses the efficacy of 19-28z CAR T-cell therapy in B-cell acute lymphoblastic leukemia.